Evidence map›Paper›PMID 27611075›Full record

ArticlePloS one2016

Stem Cell-Derived, microRNA-Carrying Extracellular Vesicles: A Novel Approach to Interfering with Mesangial Cell Collagen Production in a Hyperglycaemic Setting.

Sara Gallo, Maddalena Gili, Giusy Lombardo, Alberto Rossetti, Arturo Rosso, Patrizia Dentelli, Gabriele Togliatto, Maria Chiara Deregibus, Daniela Taverna, Giovanni Camussi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Sara GalloDepartment of Medical Sciences, University of Turin, Turin, Italy.
Maddalena GiliDepartment of Medical Sciences, University of Turin, Turin, Italy.
Giusy LombardoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Alberto RossettiDepartment of Medical Sciences, University of Turin, Turin, Italy.
Arturo RossoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Patrizia DentelliDepartment of Medical Sciences, University of Turin, Turin, Italy.
Gabriele TogliattoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Maria Chiara DeregibusDepartment of Medical Sciences, University of Turin, Turin, Italy.
Daniela TavernaDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Giovanni CamussiDepartment of Medical Sciences, University of Turin, Turin, Italy.
Maria Felice BrizziDepartment of Medical Sciences, University of Turin, Turin, Italy.
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) that are derived from stem cells are proving to be promising therapeutic options. We herein investigate the therapeutic potential of EVs that have been derived from different stem cell sources, bone-marrow (MSC) and human liver (HLSC), on mesangial cells (MCs) exposed to hyperglycaemia. By expressing a dominant negative STAT5 construct (ΔNSTAT5) in HG-cultured MCs, we have demonstrated that miR-21 expression is under the control of STAT5, which translates into Transforming Growth Factor beta (TGFβ) expression and collagen production. A number of approaches have been used to show that both MSC- and HLSC-derived EVs protect MCs from HG-induced damage via the transfer of miR-222. This resulted in STAT5 down-regulation and a decrease in miR-21 content, TGFβ expression and matrix protein synthesis within MCs. Moreover, we demonstrate that changes in the balance between miR-21 and miR-100 in the recipient cell, which are caused by the transfer of EV cargo, further contribute to providing beneficial effects. Interestingly, these effects were only detected in HG-cultured cells. Finally, it was found that HG reduced the expression of the nuclear encoded mitochondrial electron transport chain (ETC) components, CoxIV. It is worth noting that EV administration can rescue CoxIV expression in HG-cultured MCs. These results thus demonstrate that both MSC- and HLSC-derived EVs transfer the machinery needed to preserve MCs from HG-mediated damage. This occurs via the horizontal transfer of functional miR-222 which directly interferes with damaging cues. Moreover, our data indicate that the release of EV cargo into recipient cells provides additional therapeutic advantages against harmful mitochondrial signals.

Indexed as

Cell ProliferationCells, CulturedCollagenCollagen Type IVExtracellular VesiclesGlucoseHumansHyperglycemiaMesangial CellsMesenchymal Stem CellsMicroRNAsModels, BiologicalRNA Processing, Post-TranscriptionalSTAT5 Transcription FactorStem CellsCollagenCollagen Type IVGlucoseMicroRNAsSTAT5 Transcription Factor

Identifiers

PMID27611075
PMCPMC5017750
OpenAlexW2515055992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.